Letter

Learning from low income countries: Poor patients deserve more science and less advocacy

BMJ 2005; 330 doi: 10.1136/bmj.330.7489.479 (Published 24 February 2005)
Cite this as: BMJ 2005;330:479.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Carol C Adelman (carola@hudsondc.org), director,
  2. Jeremiah Norris, senior fellow
  1. Center for Science in Policy, Hudson Institute, 1015 18th Street NW, Suite 300, Washington, DC 20036, USA

    EDITOR—Hogerzeil, who works for the World Health Organization in Geneva, contends that WHO selects essential medicines within a therapeutic class on the basis of comparative efficacy, safety, and cost.1 His reference text, Essential Medicines,2 is at variance with that contention.

    WHO's choice to treat 3 million by 2005 is triple dose combination antiretroviral treatment from India. In the April listing, WHO says: “The Committee …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular